Stockreport

4DMT Reports Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 Positive interim clinical data f [Read more]